Cost may be an important factor in which version of oral PrEP you decide to take, especially if your healthcare system or insurance does not reimburse for the medication. The patent for branded ...

Apretude, Descovy, Truvada, and a generic version of Truvada—often referred to as PrEP—are approved for men at high risk of acquiring HIV. By Lisa L. Gill Updated by Justin Krajeski About ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

The Scottish Medicines Consortium has approved the use of Gilead’s Truvada for use in preventing new HIV infections, so called pre-exposure prophylaxis (PrEP). The decision has been hailed as a ...

Gilead Sciences has filed Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, in the US, spending a priority review voucher (PRV) to set up a verdict within six months.

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...

The Supreme Court will hear a challenge to Obamacare’s preventive care mandates, giving Trump a chance to reshape rules on ...

Two oral PrEP medications have been approved by the U.S. Food and Drug Administration (FDA)—Truvada and Descovy—and one injection drug called Apretude that must be taken once every two months.

(Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention ...

To learn more about using Descovy or Truvada to treat your condition, talk with your doctor. You can also see this Descovy for PrEP article. Descovy and Truvada are used to treat HIV in children.

There are three different products that are currently FDA approved for use as PrEP. These options include two, once-daily oral medications called Truvada (generic versions available), and Descovy. The ...

That the people who have taken PREP, in this case, Truvada, have not had any significant change in their behavioral patterns vis-à-vis the risks they take, which is good news.